The recognition of HAT1 in the regulation of PD-L1 expression suggests that HAT1 might be employed as a new diagnostic and prognostic marker and as a predictive marker for pancreatic cancer therapy, especially in immune checkpoint blockade therapy. Here, CD274 is linked to familial pancreatic carcinoma.